ABBV
AbbVie Inc.
Healthcare · Drug Manufacturers - General · United States · Stock
Score Breakdown
Scored for Dividend Income profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- The composite score of 51.7/100 is anchored by two strong pillars — financial health (18.0/20) and dividend (13.8/20) — which together contribute approximately 31 of the available 40 points from those two categories, reflecting AbbVie's status as a mature, cash-generative pharmaceutical operator.
- The moderate profitability sub-score of 10.4/20 adds meaningful support, reflecting the company's ability to sustain above-average net and operating margins even during a product transition cycle that has compressed top-line growth.
- The score is held in the 51.7 range rather than moving higher because growth, momentum, and theme sub-scores collectively contribute only around 15 points out of a possible 60, reflecting real filing-derived evidence of constrained near-term growth dynamics and an absence of mapped macro theme exposure.
Why Not Higher
- The zero theme score (0.0/20) is the single largest source of suppressed scoring, as the model found no macro thematic exposures in AbbVie's 10-K filing disclosures, removing a full scoring category that could otherwise add up to 20 points to the composite.
- The combined growth and momentum sub-scores of 7.5 and 7.4 respectively reflect filing-derived evidence that AbbVie has not yet demonstrated consistent quarterly improvement in revenues, earnings, or margins, preventing the model from assigning scores in the upper range of those categories.
Data Confidence
10 / 10
Very High — full data coverage
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
AbbVie Inc. is a large-cap US-based biopharmaceutical company specializing in immunology, oncology, neuroscience, and aesthetics, with key commercial franchises including Skyrizi, Rinvoq, Botox (acquired through Allergan), and the legacy immunology blockbuster Humira. The model assigned AbbVie a score of 51.7/100, reflecting a genuinely mixed financial profile as revealed through its FY2025 SEC 10-K filing. The strongest sub-scores come from financial health (18.0/20) and dividend (13.8/20), indicating that despite carrying significant debt — a hallmark of its 2020 Allergan mega-acquisition — the company maintains strong interest coverage and a well-supported dividend backed by free cash flow. Profitability also scores well at 10.4/20, consistent with the high operating margins typical of large branded pharmaceutical businesses. However, growth (7.5/20) and momentum (7.4/20) scores are moderate, reflecting the post-Humira biosimilar erosion period where the company is transitioning revenue dependency toward newer assets like Skyrizi and Rinvoq, creating near-term top-line headwinds. The theme score of 0.0/20 — meaning no macro theme exposure was mapped from the filing — also weighs on the composite total. The key research tradeoff for AbbVie is between its powerful dividend infrastructure and cash generation on one hand, and meaningful financial leverage combined with a revenue transition risk on the other. The model's best-fit profile is dividend income (61.7), not aggressive growth (41.0), which accurately captures the company's current positioning: a mature, cash-generative pharma operator rebuilding its growth engine after Humira's patent cliff. Researchers evaluating AbbVie for income-oriented purposes will find more supportive data than those seeking near-term earnings acceleration.
Plain English
AbbVie is a large American pharmaceutical company best known for Humira, one of the best-selling drugs in history, and newer medicines like Skyrizi and Rinvoq. The score of 51.7 out of 100 reflects a company that pays a solid, well-covered dividend and generates strong profits, but carries a lot of debt and is going through a challenging transition as Humira faces biosimilar competition. The Medium risk rating means there are real financial risks — mainly leverage and revenue concentration — but the business has enough cash flow and profitability to be a credible research candidate, particularly for dividend-income-focused research.
Bull Case vs. Bear Case
Bull Case
- The dividend sub-score of 13.8/20 indicates that AbbVie's dividend is strongly supported by free cash flow, with favorable FCF payout coverage and a consistent track record of dividend per share growth, making it a leading candidate within dividend-income research frameworks.
- The financial health sub-score of 18.0/20 — the highest sub-score in AbbVie's profile — suggests that despite elevated absolute leverage from the Allergan acquisition, interest coverage ratios remain robust and the balance sheet is sized appropriately relative to the company's earnings power.
- The profitability sub-score of 10.4/20 reflects AbbVie's ability to maintain strong net and operating margins even during the Humira biosimilar transition period, supported by the growing contributions of Skyrizi and Rinvoq which carry favorable margin profiles as they scale.
Bear Case
- The growth sub-score of only 7.5/20 signals that year-over-year revenue, net income, and EPS growth have been constrained, consistent with the documented headwinds from Humira biosimilar competition eroding one of the most profitable drug franchises in pharmaceutical history.
- The momentum sub-score of 7.4/20 indicates limited sequential improvement in quarterly revenue, earnings, and margins as reported in the 10-K, suggesting the Humira-to-next-generation transition has not yet produced a consistent acceleration in underlying financial performance.
- The theme score of 0.0/20 means the model found no mapped macro thematic exposure from AbbVie's filing disclosures, which reduces the composite score materially and suggests the company does not benefit from structural growth tailwinds that might otherwise support a higher overall model rating.
What Could Change the Picture
Bullish Triggers
- Sustained acceleration in Skyrizi and Rinvoq revenue contributions, as documented in subsequent annual filings, that demonstrably lifts the growth sub-score above 12/20 and the momentum sub-score above 12/20 would materially strengthen the research case.
- A reduction in absolute leverage levels through accelerated debt repayment — reflected in improved leverage ratios in future 10-K balance sheet data — combined with continued free cash flow growth supporting an increased dividend per share CAGR would strengthen both the financial health and dividend sub-scores further.
Bearish Triggers
- Evidence in future SEC filings of material deterioration in free cash flow coverage of the dividend — causing the FCF payout ratio to rise significantly — would directly pressure the dividend sub-score and undermine the primary argument for AbbVie as a dividend-income research candidate.
- Any filing-disclosed setbacks to Skyrizi or Rinvoq — such as label restrictions, competitive displacement, or pricing pressure — that cause the growth sub-score to decline further below 7.5/20 would signal that the Humira transition is failing, materially weakening the overall research profile.
Red Flags
- AbbVie's financial health sub-score of 18.0/20, while strong in coverage terms, still reflects significant absolute leverage inherited from the $63 billion Allergan acquisition, and any deterioration in operating cash flow — particularly if Skyrizi or Rinvoq face competitive or regulatory setbacks — could pressure debt-service capacity.
- The combination of a low growth sub-score (7.5/20) and low momentum sub-score (7.4/20) indicates that the financial inflection from next-generation assets has not yet fully materialized in the reported numbers, representing a timing risk for research theses dependent on near-term earnings recovery.
- Revenue concentration risk remains a structural concern embedded in AbbVie's filing disclosures, as the transition from Humira-driven revenues to a more diversified base is still underway, creating meaningful sensitivity to the performance trajectory of a small number of successor products.
Risk Profile
Medium RiskThe Medium risk rating for AbbVie reflects a company with genuinely strong cash generation and dividend coverage, but carrying elevated financial leverage from a transformative acquisition and navigating a high-stakes product revenue transition away from a single legacy blockbuster, any disruption to which could have outsized consequences for reported financials. The risk is neither low — given the leverage and concentration dynamics evident in the filing — nor high, given the demonstrated profitability and interest coverage strength captured in the financial health sub-score of 18.0/20.
Key Catalysts to Watch
The primary catalyst to watch is the trajectory of Skyrizi and Rinvoq revenue growth as disclosed in future 10-K and quarterly filings, as these two assets must scale sufficiently to offset ongoing Humira biosimilar erosion and return the growth and momentum sub-scores to levels that would support a higher composite model score. Secondary catalysts include AbbVie's progress on pipeline milestones in neuroscience and oncology, as successful approvals could introduce new thematic exposure and potentially lift the currently zero theme sub-score in future model runs.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.